R&D Systems™ Recombinant Human VSIG2 Fc Chimera Protein

Catalog No.	Quantity
98-15VS-100	100 μg

Catalog No. 98-15VS-100 Supplier R&D Systems™ Supplier No. 9815VS100

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED50 for this effect is 5-25 μg/mL.

Specifications

• Accession Number: Q96IQ7-1
• For Use With (Application): Bioactivity
• Formulation: Lyophilized from a 0.2 μm filtered solution in PBS.
• Gene ID (Entrez): 23584
• Molecular Weight (g/mol): M.W. (Observed): 54-65 kDa, reducing conditions; M.W. (theoretical): 50 kDa
• Quantity: 100 μg
• Source: Mouse myeloma cell line, NS0-derived human VSIG2 protein Human VSIG2 (Val24-Ala243) (N-terminus) Accession # Q96IQ7-1 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Storage Requirements: 12 months from date of receipt, <= -20 °C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, <= -20 °C under sterile conditions after reconstitution.
• Regulatory Status: RUO
• Endotoxin Concentration: <0.10 EU / 1 μg of the protein by the LAL method.
• Conjugate: Unconjugated
• Cross Reactivity: VSIG2
• Species: Human
• Reconstitution: Reconstitute at 500 μg/mL in PBS.
• Purity or Quality Grade: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.
• Protein: VSIG2